Chat with us, powered by LiveChat
8th Drug Formulation, Solubility & Bioavailability Summit -

8th Drug Formulation, Solubility & Bioavailability Summit
March 25 - 27, 2019
Boston, MA

The Modeling and Enabled Formulation Expertise You Need to Maximize Developability, Avoid Particle Formation, and Maintain Stability and Bioavailability

Faculty – 8th Drug Formulation, Solubility & Bioavailability Summit

Kang-Jye Chou
Scientist, GENENTECH

David Cipolla
Vice President, Research, INSMED

Ann Daugherty
Senior Manager, Drug Delivery, GENENTECH

Eric Dinarello
Senior Scientific Associate, VERTEX PHARMACEUTICALS

Helen Hao Hou
Senior Scientist, Small Molecule Pharmaceutical Sciences, GENENTECH

Keith Horspool
Vice President, Pharmaceutics, BOEHRINGER INGELHEIM

view speaker profile

Keith Horspool is Vice President of Pharmaceutical Development at Boehringer Ingelheim, Ridgefield, CT. His department encompasses predevelopment support; physical pharmaceutics; formulation development; and process technology to support API selection, solid dosage form design and process development for technology transfer. The group has a strong interest in the evaluation and implementation of new technology — including advanced materials profiling, predictive methods for pharmaceutical development and drug delivery systems — to facilitate new products to patients.

Prior to joining BI, Dr. Horspool worked at Pfizer (UK and US) and AstraZeneca. He has more than 20 years of experience, during which he has managed pre-formulation, formulation development and materials science. He has a B.Sc. in pharmacy, and a Ph.D in pharmaceutical chemistry.

Hyungchul Kim

Wei Li
Postdoctoral Fellow, Laboratory for Drug Delivery, GEORGIA INSTITUTE OF TECHNOLOGY

Craig McKelvey
Specialty Dosage Formulation Group Lead, MERCK

Eric Munson
Professor and Head, Department of Industrial and Physical Pharmacy, PURDUE UNIVERSITY

Rashmi Nair
Formulation Scientist, DR. REDDY’S

view speaker profile

Rashmi Nair is Senior Scientist (Pharmaceutical Product Development) at Dr. Reddy’s Laboratories Ltd., India. She is a qualified pharmaceutical professional with supplementary roles of Lead Technical Associate to business and is certified in intellectual property/patents. In the last decade of her work at Custom Pharmaceutical Services (CPS) division of Dr. Reddy’s, she and her team have worked with various innovator companies from the USA, Europe and Asia Pacific for the development of proprietary technologies and have specialized in bioavailability enhancement techniques for new chemical entities and repurposed drugs in clinical studies. The focus of her work, as reflected in her international papers and presentations, has been to highlight the importance of simplified innovation and integrated development between chemistry, preformulation, formulation and manufacturing teams. Her presentation for the 6th Drug Formulation, Solubility & Bioavailability conference focuses on distinct development needs at various stages of a clinical phase molecule.

Katharine Odneal
Senior Formulation Scientist, Research and Development, NESHER

Dhaval Patel
Senior Research Investigator, BRISTOL-MYERS SQUIBB

Robert Prud'homme
Professor, Chemical and Biological Engineering, PRINCETON UNIVERSITY

Lilly Roy

Aliasger Salem
Head, Division of Pharmaceutics and Translational Therapeutics, UNIVERSITY OF IOWA

Manuel Sanchez-Felix
Senior Fellow, Formulation, NOVARTIS

view speaker profile

Dr. Manuel Sanchez-Felix is a Senior Fellow with the Chemical and Pharmaceutical Profiling (CPP) group at the Novartis Institutes for BioMedical Research in Cambridge, MA. He is a scientific leader with over 20 years of experience in drug discovery and development where he co-invented products and contributed to the successful development and launch of various pharmaceutical products.

At Novartis, Dr. Sanchez-Felix leads a cross-functional group from Discovery and Development that is responsible for the evaluation and implementation of external Novel Delivery Technologies. His previous position at Novartis involved heading a group of scientists at the interface between Research and Development, establishing physicochemical and biopharmaceutical properties, and combining this information to initiate development strategy and formulation design. Prior to joining Novartis, Manuel was at Eli Lilly & Company for 20 years. His area of expertise includes Biopharmaceutics, drug delivery, and patient-centered formulation design. Areas of drug discovery were he has developed products include CNS, infectious diseases (specifically TB), oncology, bone regeneration, and diabetes.

Dr. Sanchez-Felix received his B.Sc. Honors degree and Ph.D. in Chemistry from the University of Surrey, UK. He is also an Adjunct Professor in the Department of Industrial and Physical Pharmacy at Purdue University (West Lafayette, IN) and a Fellow of the Royal Society of Chemistry. Recently, he has joined the Advisory Board for the Biomedical Program at Middlesex Community College and is a member of the Scientific Advisory Board member of an instrument company.

Wei Xu
Director, Preformulation, MERCK

Tao Zhang
Principal Scientist, Drug Product Design, PFIZER

live chat software